Page 6 - Cancer Drugs

Venus Remedies gets marketing approval for 6 chemo drugs from Philippines

Pharma major Venus Remedies on Monday said it has received marketing approval from the Philippines for six key chemotherapy drugs. The approved drugs include bortezomib, cisplatin, doxorubicin, docetaxel, fluorouracil, and paclitaxel, which are crucial for cancer treatment, according to a company statement. With this, Venus Remedies has secured 525 marketing approvals for its oncology products across 76 countries, it said. This achievement marks a significant step towards achieving the company's goal of emerging as the top oncology medicine supplier from India in Southeast Asia, said Saransh Chaudhary, chief executive officer, Venus Medicine Research Centre. "While oncology drugs account for 157 of our 205 marketing authorisations in the ASEAN region, we are banking on these product registrations from the Philippines to pave the way for faster approval of these drugs in other Southeast Asian countries as well," Chaudhary added. The company will further extend its operations to oth

Over 6 of every 10 cancer deaths in Indian women were preventable: Lancet

The study said that the value of unpaid cancer caregiving in India was 2.53 per cent of its national health expenditure

Natco Pharma, Celgene Corp, others sued in US for generic cancer drug

Natco Pharma on Friday said the company and other drug makers have been named defendants in an antitrust lawsuit regarding a generic cancer treatment drug in the US. The Hyderabad-based drug firm along with Celgene Corporation, Bristol Myers Squibb, Breckenridge Pharmaceutical Inc and others have been named defendants by Louisiana Health Service & Indemnity Company, D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc, regarding anti-cancer treatment medication Pomalidomide. The company believes this matter is without merit, Natco Pharma said in a statement. Breckenridge is the abbreviated new drug application (ANDA) holder and distribution partner for the generic product in the US, it added. Natco Pharma shares were trading 3.13 per cent down at Rs 885.00 apiece on the BSE.

England's NHS introduces 7-minute 'under the skin' cancer treatment

This new method allows cancer patients to receive the immunotherapy drug 'Atezolizumab' through an injection, as opposed to intravenous administration which can take up to an hour

Venus Remedies gets market authorisations for cancer drugs from 4 nations

Pharma major Venus Remedies on Monday said it has received market authorisations for its key cancer drugs from Philippines, Paraguay, Georgia and Moldova. With this, the company has secured 506 marketing approvals for its oncology products across 76 countries. While Venus Remedies has secured marketing approval for topotecan from Philippines, it has also reinforced its position as a leading exporter of oncology drugs with product registration for irinotecan in Paraguay, docetaxel in Georgia and topotecan and irinotecan in Moldova, said the company in a statement. "This accomplishment is a decisive move towards achieving our goal of emerging as the top oncology medicine supplier from India in the Association of Southeast Asian Nations (ASEAN) region and further expanding the reach of our cancer drugs in South America and Eastern Europe. With these marketing authorisations, the company will be able to further extend its operations to new markets offering "advanced cancer treatment ..

J&J raises profit forecast as it bets on cancer drugs, medical devices

Shares of J&J, which recently spun off its consumer health unit to focus on drugs and medical devices, rose about 2% in premarket trading

GST Council may exempt IGST on cancer drug import at next meeting

The GST Council at its next meeting on Tuesday is likely to exempt cancer medicine Dinutuximab imported by individuals from tax, decide on applicability of GST on food or beverages served in multiplexes and come out with a clear definition of utility vehicles for levying a 22 per cent cess, sources said. The Council, chaired by Union finance minister and comprising state ministers, will also decide on GST exemption for satellite launch services provided by private players. Besides, import of medicines and Food for Special Medical Purposes (FSMP) used in the treatment of rare diseases for personal use and also by centres of excellence are likely to be exempted from Integrated GST. Currently, such imports attract an IGST of 5 per cent or 12 per cent. The fitment committee, comprising central and state tax officers, has recommended to the Council to clarify on these major issues at the 50th meeting of the Council on July 11. In addition to the recommendations of the fitment committee,

AstraZeneca's cancer drug shows more potential over chemotherapy: Study

The results potentially validate Astra's decision to pay as much as $6 billion for the right to develop the medicine with Daiichi Sankyo Co. and its bet to revive growth a decade ago

Lupin gets $25 mn from AbbVie for meeting key product development milestone

Drug firm Lupin on Thursday said it has received USD 25 million (around Rs 205 crore) from AbbVie Inc for meeting a key development milestone for a product to treat hematological cancers. The company has achieved a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program that is partnered with AbbVie Inc towards treatment across a range of hematological cancers, the Mumbai-based drug maker said in a statement. As part of the agreement, Lupin has received USD 25 million from AbbVie for initiation of Phase 1 clinical studies successfully, it added. The drug maker had earlier received USD 30 million from AbbVie for achievement of other milestones in the programme. "This achievement is further validation of our ability to successfully develop novel treatments for unmet needs. We look forward to continued successful development of this important treatment for patients with difficult-to-treat cancers," Lupin Managing Directo

US FDA to temporarily import Chinese cancer drug to ease shortage

Cisplatin, a generic drug available for decades in the US, has faced national shortage since February after an Indian pharmaceutical company temporarily halted production for the US market

New combination therapy cuts risk of breast cancer returning by 25%

The median duration of study follow-up was 34 months, with three-year and two-year duration of ribociclib completed by 20 per cent and 57 per cent patients respectively

Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe

Sun Pharmaceutical Industries on Tuesday said it has entered into a licensing pact with Philogen SpA to commercialise under-development skin cancer drug in Europe, Australia and New Zealand. The companies have come together to commercialise Philogen's speciality product Nidlegy, an anti-cancer biopharmaceutical currently in Phase III clinical trials, Sun Pharma said in a statement. Philogen, a Swiss-Italian firm, is developing it for the treatment of melanoma and non-melanoma skin cancers. Under the terms of the agreement, the Mumbai-based drug major will have exclusive rights to commercialise Nidlegy. Philogen will complete pivotal clinical trials for the product in Europe, pursue marketing authorisation with the regulatory authorities and manufacture commercial supplies. The two partner companies will share post-commercialisation economics in about a 50:50 ratio, the drug major said. While other financial terms were not disclosed, Philogen will retain the IP rights for Nidlegy

US FDA panel backs restricted use of AstraZeneca's prostate cancer drug

Lynparza is already approved by the FDA to treat a type of breast cancer, ovarian cancer, as well as a different form of prostate cancer

J&J May Need to Defend Baby Powder Cancer Suits After 19-Month Pause

The company says it has a deal backed by as many as 80,000 claimants, which should be enough to meet a key legal threshold to push a settlement worth $8.9 billion through bankruptcy

BioNTech signs deal to co-develop OncoC4's cancer antibody drug

A late-stage trial for the drug has been planned for this year, the companies said

Seagen acquisition: Pfizer can now bet on future of cancer drugs

Given the muted response to the deal on Monday, analysts seem skeptical that this will be as easy as Pfizer makes it sound

AstraZeneca gets CDSCO nod for drug to treat biliary tract cancer

Drug firm AstraZeneca India on Friday said it has received approval from the domestic drug regulator to market a drug to treat biliary tract cancer (BTC) in the country. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Durvalumab, the drug firm said in a statement. BTC is a group of rare and aggressive gastrointestinal (GI) cancers that form in the cells of the bile ducts (cholangiocarcinoma), gallbladder or ampulla of Vater (where the bile duct and pancreatic duct connect to the small intestine). Apart from ampullary cancer, early-stage BTC often presents without clear symptoms and most new cases of BTC are therefore diagnosed at an advanced stage, when treatment options are limited, and the prognosis is poor. More than 30,000 new cases of BTC are seen in India every year with 90 per cent of them diagnosed in the advanced stage. "The approval underpins our commitment to transform patient outcomes by harnessing the power of science

Glenmark Pharma inks settlement pact with Pfizer for cancer treatment drug

Glenmark Pharmaceuticals on Tuesday said it has entered into a settlement agreement with Pfizer Inc regarding a cancer treatment drug. The Mumbai-based drug maker and its US-based unit have inked a settlement pact with drug major Pfizer Inc for Axitinib Tablets (1 mg and 5 mg). Glenmark's product is the generic version of Pfizer's Inlyta tablets, used to treat kidney cancer. According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta tablets (1 mg and 5 mg) achieved annual sales of around USD 644.5 million. Glenmark said its current portfolio consists of 177 products authorised for distribution in the US marketplace and 47 abbreviated new drug applications (ANDA's) are pending for approval with the US Food and Drug Administration. Shares of of the drug maker were trading 1.54 per cent up at Rs 417.9 apiece on BSE.

Novartis signs world's first licensing deal for high-priced cancer drug

The oral drug, nilotinib, is used to treat chronic myeloid leukemia and may be made in Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines, and Tunisia

Q3 results: Johnson & Johnson beats estimates on demand for cancer drug

The company said it expects some impact of inflation to ease next year but higher costs of inventory manufactured in 2022 could weigh on 2023 profit